On September 4, Agilent Technologies (NYSE:A) launched a slide scanner in the United States that can maintain up to 540 glass slides at once. The Agilent S540MD has FDA clearance and targets labs buried in samples and eyeing AI-assisted workflows. The launch is straightforward to overlook, but it arrives alongside a robust quarter, and that pairing is what makes it price a look. Here’s what the information provides to the story, and what it leaves open.
Built For Busy Labs
Start with the downside it solves. Pathology labs are handling more samples and feeling more stress to flip out diagnoses sooner, all while preparing for AI-driven workflows. The S540MD is constructed for that quantity. It takes up to 540 slides, can be refilled while it runs, and matches commonplace racks, so it slots into a lab’s present setup instead of forcing a rebuild. Automated scan modes and tissue detection take on more of the routine work. Majken Nielsen, who runs Agilent’s Clinical Diagnostics Division, framed the scanner as a approach to tie digitization to clients’ staining workflows. And this is not a cold begin. The scanner reached choose European markets in January, and it now sells in the United States alongside Germany, the UK, France, and a long checklist of other European international locations.
On August 26, Agilent reported income of $1.88 billion for the quarter ended July 31, up 8.1% from a yr earlier. Non-GAAP earnings per share rose 18%, a signal that gross sales growth is reaching the backside line. CEO Padraig McDonnell credited higher finish markets, stronger regional demand and a heat response to new merchandise, which is the type of backdrop a recent launch desires. Management then raised its full-year non-GAAP earnings steering to $6.18 to $6.21 per share, exhibiting it expects the power to proceed.
Asterisks On The Good News
Now for the asterisks. The S540MD is actually a rebadged Hamamatsu NanoZoomer S540MD, so the underlying {hardware} comes from someone else. Agilent’s edge has to come from its pathology experience and how neatly the scanner plugs into its staining workflows, which is more durable to measure than a spec sheet. The announcement also provides no pricing, no unit targets, and no income estimate, so outsiders can’t say how much this provides to the high line.
The quarter behind the launch has wonderful print of its own. Tariff refunds added $0.06 to non-GAAP earnings per share, and they also feed into the raised full-year outlook. The fourth-quarter information assumes no more refunds. It also calls for core income growth of 5.2% to 6.2%, a step down from the 7.3% core tempo in the third quarter.